Chronic Myeloid Leukemia Coverage from Every Angle

Role of Long Noncoding RNA H19 in CML

By: Sarah Campen, PharmD
Posted: Monday, May 18, 2020

The expression of the long noncoding RNA H19 is reduced in chronic myeloid leukemia (CML), according to research published in Molecular Therapy Nucleic Acids. Juhua Yang, PhD, of the Medical College of Jinan University, Guangzhou, China, found that overexpression of H19 in K562 cell line cultures and the bone marrow mononuclear cells of patients with CML appeared to significantly inhibit cell growth and colony-formation ability. Overexpression of H19 also prolonged survival in CML cell lines and xenograft mice models.

The expression of H19 in blood samples of four healthy patients was compared with three patients with CML; decreased H19 expression was observed in all cancer cells compared with the healthy controls. Next, the researchers identified the H19 target proteins and microRNAs using a combination of computational prediction and RNA pull-down. By inhibiting these H19 targets—PCBP1, FUS protein, microRNA-19a-3p, and microRNA-106b-5p—cell growth and colony formation of CML cell lines was significantly reduced. Conversely, co-overexpression of H19 and PCBP1, FUS protein, microRNA-19a-3p, and microRNA-106b-5p decreased the inhibitory effect of H19.

“These findings might provide a novel molecular insight into CML,” concluded the authors. “H19 might provide a new treatment strategy for CML.”

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.